Halozyme Therapeutics Statistics
Share Statistics
Halozyme Therapeutics has 127.23M shares outstanding. The number of shares has increased by -3.97% in one year.
| Shares Outstanding | 127.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.47% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 125.88M |
| Failed to Deliver (FTD) Shares | 24 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 10.25M, so 8.06% of the outstanding shares have been sold short.
| Short Interest | 10.25M |
| Short % of Shares Out | 8.06% |
| Short % of Float | 8.14% |
| Short Ratio (days to cover) | 7.75 |
Valuation Ratios
The PE ratio is 17.32 and the forward PE ratio is 12.32. Halozyme Therapeutics 's PEG ratio is 0.14.
| PE Ratio | 17.32 |
| Forward PE | 12.32 |
| PS Ratio | 5.88 |
| Forward PS | 5.3 |
| PB Ratio | 58.18 |
| P/FCF Ratio | 13.06 |
| PEG Ratio | 0.14 |
Enterprise Valuation
Halozyme Therapeutics Inc. has an Enterprise Value (EV) of 6.26B.
| EV / Earnings | 22.22 |
| EV / Sales | 7.55 |
| EV / EBITDA | 13.84 |
| EV / EBIT | 18.53 |
| EV / FCF | 16.76 |
Financial Position
The company has a current ratio of 6.64, with a Debt / Equity ratio of 17.89.
| Current Ratio | 6.64 |
| Quick Ratio | 5.5 |
| Debt / Equity | 17.89 |
| Total Debt / Capitalization | 94.71 |
| Cash Flow / Debt | 0.26 |
| Interest Coverage | 17.99 |
Financial Efficiency
Return on equity (ROE) is 3.36% and return on capital (ROIC) is 17.24%.
| Return on Equity (ROE) | 3.36% |
| Return on Assets (ROA) | 0.16% |
| Return on Capital (ROIC) | 17.24% |
| Revenue Per Employee | 2.22M |
| Profits Per Employee | 754.94K |
| Employee Count | 373 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.51 |
Taxes
| Income Tax | 66.73M |
| Effective Tax Rate | 0.19 |
Stock Price Statistics
The stock price has increased by 22.96% in the last 52 weeks. The beta is 1.29, so Halozyme Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.29 |
| 52-Week Price Change | 22.96% |
| 50-Day Moving Average | 51.89 |
| 200-Day Moving Average | 50 |
| Relative Strength Index (RSI) | 42.51 |
| Average Volume (20 Days) | 1.66M |
Income Statement
In the last 12 months, Halozyme Therapeutics had revenue of $829.25M and earned $281.59M in profits. Earnings per share was $2.13.
| Revenue | 829.25M |
| Gross Profit | 636.89M |
| Operating Income | 337.57M |
| Net Income | 281.59M |
| EBITDA | 451.95M |
| EBIT | 337.57M |
| Earnings Per Share (EPS) | 2.13 |
Balance Sheet
The company has $118.37M in cash and $1.50B in debt, giving a net cash position of -$1.38B.
| Cash & Cash Equivalents | 118.37M |
| Total Debt | 1.50B |
| Net Cash | -1.38B |
| Retained Earnings | 90.55M |
| Total Assets | 2.12B |
| Working Capital | 1.02B |
Cash Flow
In the last 12 months, operating cash flow was $388.57M and capital expenditures -$15.29M, giving a free cash flow of $373.28M.
| Operating Cash Flow | 388.57M |
| Capital Expenditures | -15.29M |
| Free Cash Flow | 373.28M |
| FCF Per Share | 2.83 |
Margins
Gross margin is 76.8%, with operating and profit margins of 40.71% and 33.96%.
| Gross Margin | 76.8% |
| Operating Margin | 40.71% |
| Pretax Margin | 42.01% |
| Profit Margin | 33.96% |
| EBITDA Margin | 54.5% |
| EBIT Margin | 40.71% |
| FCF Margin | 45.01% |
Dividends & Yields
HALO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 4.44% |
| FCF Yield | 6.11% |
Analyst Forecast
The average price target for HALO is $62, which is 29.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $62 |
| Price Target Difference | 29.2% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 4.22 |
| Piotroski F-Score | 8 |